Carcinoid heart disease

Alain M. Bernheim, Heidi M. Connolly, Patricia Pellikka

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

In patients with carcinoid heart disease, a multidisciplinary approach to patient are is required because treatment of the systemic disease and management of cardiac involvement must be considered at the same time. Somatostatin analogue use is a therapeutic cornerstone, effective in symptomatic control of the endocrine syndrome. Chemotherapy is of limited efficacy in patients with carcinoid tumors. Hepatic resection of metastases is the preferred treatment option and has been shown to result in improved outcome. It should be considered if at least 90% of the metastases in the liver are removable. Hepatic artery embolization is usually applied if a patient is not eligible for surgical debulking. Development and progression of carcinoid heart disease complicate the carcinoid syndrome and contribute to poor prognosis. In patients with severe cardiac involvement and well-controlled systemic disease, valve replacement surgery is an effective treatment modality that can relieve intractable symptoms and contribute to improved outcome.

Original languageEnglish (US)
Pages (from-to)482-489
Number of pages8
JournalCurrent Treatment Options in Cardiovascular Medicine
Volume9
Issue number6
DOIs
StatePublished - 2007

Fingerprint

Carcinoid Heart Disease
Carcinoid Tumor
Neoplasm Metastasis
Liver
Hepatic Artery
Therapeutics
Disease Management
Somatostatin
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Carcinoid heart disease. / Bernheim, Alain M.; Connolly, Heidi M.; Pellikka, Patricia.

In: Current Treatment Options in Cardiovascular Medicine, Vol. 9, No. 6, 2007, p. 482-489.

Research output: Contribution to journalReview article

Bernheim, Alain M. ; Connolly, Heidi M. ; Pellikka, Patricia. / Carcinoid heart disease. In: Current Treatment Options in Cardiovascular Medicine. 2007 ; Vol. 9, No. 6. pp. 482-489.
@article{3c1588596fb24a139d79a15dfd347824,
title = "Carcinoid heart disease",
abstract = "In patients with carcinoid heart disease, a multidisciplinary approach to patient are is required because treatment of the systemic disease and management of cardiac involvement must be considered at the same time. Somatostatin analogue use is a therapeutic cornerstone, effective in symptomatic control of the endocrine syndrome. Chemotherapy is of limited efficacy in patients with carcinoid tumors. Hepatic resection of metastases is the preferred treatment option and has been shown to result in improved outcome. It should be considered if at least 90{\%} of the metastases in the liver are removable. Hepatic artery embolization is usually applied if a patient is not eligible for surgical debulking. Development and progression of carcinoid heart disease complicate the carcinoid syndrome and contribute to poor prognosis. In patients with severe cardiac involvement and well-controlled systemic disease, valve replacement surgery is an effective treatment modality that can relieve intractable symptoms and contribute to improved outcome.",
author = "Bernheim, {Alain M.} and Connolly, {Heidi M.} and Patricia Pellikka",
year = "2007",
doi = "10.1007/s11936-007-0043-0",
language = "English (US)",
volume = "9",
pages = "482--489",
journal = "Current Treatment Options in Cardiovascular Medicine",
issn = "1092-8464",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Carcinoid heart disease

AU - Bernheim, Alain M.

AU - Connolly, Heidi M.

AU - Pellikka, Patricia

PY - 2007

Y1 - 2007

N2 - In patients with carcinoid heart disease, a multidisciplinary approach to patient are is required because treatment of the systemic disease and management of cardiac involvement must be considered at the same time. Somatostatin analogue use is a therapeutic cornerstone, effective in symptomatic control of the endocrine syndrome. Chemotherapy is of limited efficacy in patients with carcinoid tumors. Hepatic resection of metastases is the preferred treatment option and has been shown to result in improved outcome. It should be considered if at least 90% of the metastases in the liver are removable. Hepatic artery embolization is usually applied if a patient is not eligible for surgical debulking. Development and progression of carcinoid heart disease complicate the carcinoid syndrome and contribute to poor prognosis. In patients with severe cardiac involvement and well-controlled systemic disease, valve replacement surgery is an effective treatment modality that can relieve intractable symptoms and contribute to improved outcome.

AB - In patients with carcinoid heart disease, a multidisciplinary approach to patient are is required because treatment of the systemic disease and management of cardiac involvement must be considered at the same time. Somatostatin analogue use is a therapeutic cornerstone, effective in symptomatic control of the endocrine syndrome. Chemotherapy is of limited efficacy in patients with carcinoid tumors. Hepatic resection of metastases is the preferred treatment option and has been shown to result in improved outcome. It should be considered if at least 90% of the metastases in the liver are removable. Hepatic artery embolization is usually applied if a patient is not eligible for surgical debulking. Development and progression of carcinoid heart disease complicate the carcinoid syndrome and contribute to poor prognosis. In patients with severe cardiac involvement and well-controlled systemic disease, valve replacement surgery is an effective treatment modality that can relieve intractable symptoms and contribute to improved outcome.

UR - http://www.scopus.com/inward/record.url?scp=36749045322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749045322&partnerID=8YFLogxK

U2 - 10.1007/s11936-007-0043-0

DO - 10.1007/s11936-007-0043-0

M3 - Review article

VL - 9

SP - 482

EP - 489

JO - Current Treatment Options in Cardiovascular Medicine

JF - Current Treatment Options in Cardiovascular Medicine

SN - 1092-8464

IS - 6

ER -